{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:00:27Z","timestamp":1770505227717,"version":"3.49.0"},"reference-count":25,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Chemotherapy"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1179\/joc.2006.18.5.545","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T13:05:49Z","timestamp":1389272749000},"page":"545-548","source":"Crossref","is-referenced-by-count":9,"title":["Chemotherapeutic Management of Small Bowel Adenocarcinoma Associated with Crohn's Disease"],"prefix":"10.1080","volume":"18","author":[{"given":"H.W.","family":"Bruckner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.R","family":"Hrehorovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.S.","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.I","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Coopeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,7,18]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"1364","article-title":"Management of small bowel adenocarcinoma","volume":"16","author":"Kummar S","year":"2002","unstructured":"Kummar S, Ciesilski TE, Fogarasi MC. Management of small bowel adenocarcinoma. Oncology 2002; 16: 1364\u20139.","journal-title":"Oncology"},{"key":"e_1_2_1_3_1","first-page":"529","article-title":"An overview of adenocarcinoma of the small intestine","volume":"11","author":"Neugut Al","year":"1997","unstructured":"Neugut Al, Marvin MR, ReIla VA, Chabot JA. An overview of adenocarcinoma of the small intestine. Oncology 1997; 11: 529\u201336.","journal-title":"Oncology"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20404"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200401000-00005"},{"key":"e_1_2_1_6_1","first-page":"434","article-title":"Malignancy in Crohn's disease","volume":"9","author":"Bernstein D","year":"1996","unstructured":"Bernstein D, Rogers A. Malignancy in Crohn's disease. Am J Gastroenterol. 1996; 9: 434\u201340.","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_1_7_1","first-page":"45","article-title":"Adenocarcinoma of small bowel: a study of 37 cases with emphasis on histologic prognostic factors","volume":"2002","author":"Abraham NA","unstructured":"Abraham NA, Halverson A, Fazio VW, Rybicki LA, Goldblum JR. Adenocarcinoma of small bowel: a study of 37 cases with emphasis on histologic prognostic factors. Dis Colon Rectum 2002; 45: 1496-502.","journal-title":"Dis Colon Rectum"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-002-0038-6"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0720-048X(02)00034-7"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199906000-00003"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840101)53:1<23::AID-CNCR2820530106>3.0.CO;2-U"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.523"},{"key":"e_1_2_1_13_1","unstructured":"Copson ER Darby A Harvey M Geldart T Iverson TJ. Epirubicin cisplatin and infusional 5-fluorouracil chemotherapy for locally advanced and metastatic small bowel adenocarcinoma. Proc Am Soc Clin Oncol 2002: abstract 2347."},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-2-132"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2003.15.5.503"},{"key":"e_1_2_1_16_1","unstructured":"Czaykowski.P Hui D. Partial response to irinotecan as second line chemotherapy for small bowel adenocarcinoma (SBA): experience over a 10-year period at the BC cancer agency. 2004 ASCO Gastrointestinal Symposium; Abstract 109."},{"key":"e_1_2_1_17_1","unstructured":"Janat MM Zhou GZ Bruckner HW Szajer L Coopermann A Kurbacher C. Drug interactions demonstrable in an ex vivo ATP assay system for gastrointestinal cancers. Am Assoc Cancer Res 1999; 40: 3459 abstract 2286."},{"key":"e_1_2_1_18_1","first-page":"203","article-title":"Drug interaction based laboratory designed combination chemotherapy for pancreatic cancer","author":"Bruckner HW","year":"2003","unstructured":"Bruckner HW, Bathini D, Zak D, DeGregorio P, Marino J, Zhou G. Drug interaction based laboratory designed combination chemotherapy for pancreatic cancer. International Congress on Anti-Cancer Treatment Proceedings 2003: 203.","journal-title":"International Congress on Anti-Cancer Treatment Proceedings"},{"key":"e_1_2_1_19_1","first-page":"276","article-title":"PSA and Prostate cancer, response to low dose intensity chemotherapy","author":"Bruckner HW","year":"2003","unstructured":"Bruckner HW, Bathini D, Zak D, DeGregroio P, Marino J, Zhou G. PSA and Prostate cancer, response to low dose intensity chemotherapy. International Congress on Anti-Cancer Treatment Proceedings 2003: 276.","journal-title":"International Congress on Anti-Cancer Treatment Proceedings"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.6-6-488"},{"key":"e_1_2_1_21_1","first-page":"19","article-title":"Irinotecan and gemcitabine in patients with solid tumors: phase I trial","volume":"16","author":"Rocha Lima CM","year":"2002","unstructured":"Rocha Lima CM, Leong SS, Sherman CA, et al. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Huntingt) 2002; 16: 19\u201324.","journal-title":"Oncology (Huntingt)"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601783"},{"key":"e_1_2_1_23_1","unstructured":"Hagipantelli R Saliba F Misset JL. Pathophysiology and therapy of Irinotecan (CPT-11) induced delayed onset diarrhea: a prospective assessment. Proc Am Soc Clin Oncol 1995; 14: 464 abstract 1499."},{"key":"e_1_2_1_24_1","first-page":"43","article-title":"Single agent gemcitabine and gemc-itabine\/irinotecan combination (irinogem) in non small cell lung cancer","volume":"26","author":"Rocha Lima CM","year":"1999","unstructured":"Rocha Lima CM, Eckardt JR, Leong SS, Sherman CA, Perkel JA, Putman T. Single agent gemcitabine and gemc-itabine\/irinotecan combination (irinogem) in non small cell lung cancer. Semin Oncol 1999; 26: 43\u201350.","journal-title":"Semin Oncol"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2745"},{"key":"e_1_2_1_26_1","first-page":"619","article-title":"Chemotherapy of gynecological tumors with platinum","volume":"7","author":"Bruckner HW","year":"1977","unstructured":"Bruckner HW, Cohen CJ, Deppe G, et al. Chemotherapy of gynecological tumors with platinum. J Clin Hemato Oncol 1977; 7: 619\u2013632.","journal-title":"J Clin Hemato Oncol"}],"container-title":["Journal of Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1179\/joc.2006.18.5.545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:53:11Z","timestamp":1770418391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1179\/joc.2006.18.5.545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1179\/joc.2006.18.5.545"],"URL":"https:\/\/doi.org\/10.1179\/joc.2006.18.5.545","relation":{},"ISSN":["1120-009X","1973-9478"],"issn-type":[{"value":"1120-009X","type":"print"},{"value":"1973-9478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}